KYOUNG BAEK: Open Payments
NPI 1982159174 · ENGLEWOOD CLIFFS, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$619 in 17 payments from 9 companies in 2025. Trend: 2023 $89 · 2024 $694 · 2025 $619
Food & beverage: $619
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 3 | $256 |
| GlaxoSmithKline, LLC. | 2 | $139 |
| Janssen Biotech, Inc. | 4 | $82 |
| GENZYME CORPORATION | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| ABBVIE INC. | 1 | $15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $14 |
Products named: REZDIFFRA, NUCALA, TREMFYA, DUPIXENT, TRELEGY ELLIPTA, ENTYVIO, VOQUEZNA, ZENPEP.
Industry payments across NJ — which companies pay providers there.
